Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence: The COMBINE Study: A Randomized Controlled Trial
Raymond F. Anton,Stephanie S. O'Malley,Domenic A. Ciraulo,Ron A. Cisler,David Couper,Dennis M. Donovan,David R. Gastfriend,James D. Hosking,Bankole A. Johnson,Joseph S. LoCastro,Richard Longabaugh,Barbara J. Mason,Margaret E. Mattson,William R. Miller,Helen M. Pettinati,Carrie L. Randall,Robert M. Swift,Roger D. Weiss,Lauren D. Williams,Allen Zweben +19 more
Reads0
Chats0
TLDR
Patients receiving medical management with naltrexone, CBI, or both fared better on drinking outcomes, whereas acamprosate showed no evidence of efficacy, with or without CBI.Abstract:
ContextAlcohol dependence treatment may include medications, behavioral therapies, or both. It is unknown how combining these treatments may impact their effectiveness, especially in the context of primary care and other nonspecialty settings.ObjectivesTo evaluate the efficacy of medication, behavioral therapies, and their combinations for treatment of alcohol dependence and to evaluate placebo effect on overall outcome.Design, Setting, and ParticipantsRandomized controlled trial conducted January 2001-January 2004 among 1383 recently alcohol-abstinent volunteers (median age, 44 years) from 11 US academic sites with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, diagnoses of primary alcohol dependence.InterventionsEight groups of patients received medical management with 16 weeks of naltrexone (100 mg/d) or acamprosate (3 g/d), both, and/or both placebos, with or without a combined behavioral intervention (CBI). A ninth group received CBI only (no pills). Patients were also evaluated for up to 1 year after treatment.Main Outcome MeasuresPercent days abstinent from alcohol and time to first heavy drinking day.ResultsAll groups showed substantial reduction in drinking. During treatment, patients receiving naltrexone plus medical management (n = 302), CBI plus medical management and placebos (n = 305), or both naltrexone and CBI plus medical management (n = 309) had higher percent days abstinent (80.6, 79.2, and 77.1, respectively) than the 75.1 in those receiving placebos and medical management only (n = 305), a significant naltrexone × behavioral intervention interaction (P = .009). Naltrexone also reduced risk of a heavy drinking day (hazard ratio, 0.72; 97.5% CI, 0.53-0.98; P = .02) over time, most evident in those receiving medical management but not CBI. Acamprosate showed no significant effect on drinking vs placebo, either by itself or with any combination of naltrexone, CBI, or both. During treatment, those receiving CBI without pills or medical management (n = 157) had lower percent days abstinent (66.6) than those receiving placebo plus medical management alone (n = 153) or placebo plus medical management and CBI (n = 156) (73.8 and 79.8, respectively; P<.001). One year after treatment, these between-group effects were similar but no longer significant.ConclusionsPatients receiving medical management with naltrexone, CBI, or both fared better on drinking outcomes, whereas acamprosate showed no evidence of efficacy, with or without CBI. No combination produced better efficacy than naltrexone or CBI alone in the presence of medical management. Placebo pills and meeting with a health care professional had a positive effect above that of CBI during treatment. Naltrexone with medical management could be delivered in health care settings, thus serving alcohol-dependent patients who might otherwise not receive treatment.Trial Registrationclinicaltrials.gov Identifier: NCT00006206read more
Citations
More filters
Journal ArticleDOI
Prevalence, Correlates, Disability, and Comorbidity of DSM-IV Alcohol Abuse and Dependence in the United States: Results From the National Epidemiologic Survey on Alcohol and Related Conditions
TL;DR: Comorbidity of alcohol dependence with other substance disorders appears due in part to unique factors underlying etiology for each pair of disorders studied while comorbidities of alcohol addiction with mood, anxiety, and personality disorders appears more attributable to factors shared among these other disorders.
Journal ArticleDOI
Dopamine in drug abuse and addiction: results from imaging studies and treatment implications
TL;DR: It is postulate that decreased dopamine function in addicted subjects results in decreased sensitivity to nondrug-related stimuli (including natural reinforcers) and disrupts frontal inhibition, both of which contribute to compulsive drug intake and impaired inhibitory control.
Journal ArticleDOI
A Meta-Analysis of Motivational Interviewing: Twenty-Five Years of Empirical Studies.
TL;DR: In this paper, the authors investigated the unique contribution motivational interviewing (MI) has on counseling outcomes and how MI compares with other interventions, and found that MI is more effective than other interventions.
Journal ArticleDOI
Screening, Brief Intervention, and Referral to Treatment (SBIRT): Toward a Public Health Approach to the Management of Substance Abuse.
Thomas F. Babor,Bonnie McRee,Patricia A. Kassebaum,Paul L. Grimaldi,Kazi Ahmed,Jeremy W. Bray +5 more
TL;DR: The results of these efforts demonstrate the cumulative benefit of translational research on health care delivery systems and substance abuse policy and that SBIRT yields short-term improvements in individuals' health is irrefutable.
Journal ArticleDOI
Pharmacotherapy for Adults With Alcohol Use Disorders in Outpatient Settings A Systematic Review and Meta-analysis
Daniel E Jonas,Halle R Amick,Cynthia Feltner,Georgiy Bobashev,Kathleen C. Thomas,Roberta Wines,Mimi M. Kim,Mimi M. Kim,Ellen Shanahan,C Elizabeth Gass,Cassandra J Rowe,James C. Garbutt +11 more
TL;DR: In this paper, the authors compared acamprosate to naltrexone and found no statistically significant difference between them for return to any drinking (RD, 0.14 to 0.03) or heavy drinking.
References
More filters
Journal Article
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
R C Turner,Rury R. Holman,Irene M Stratton,Carole A. Cull,David R Matthews,Susan E. Manley,V Frighi,D Wright,Andrew Neil,E M Kohner,H McElroy,C Fox,D R Hadden,Grp Ukpds. +13 more
TL;DR: Since intensive glucose control with metformin appears to decrease the risk of diabetes-related endpoints in overweight diabetic patients, and is associated with less weight gain and fewer hypoglycaemic attacks than are insulin and sulphonylureas, it may be the first-line pharmacological therapy of choice in these patients.
Book
Motivational interviewing: preparing people for change.
TL;DR: In this article, the authors present a discussion of the effectiveness of Motivational Interviewing in the treatment of dual disorders and its adaptation in medical and public health settings, as well as a practical case example.
Journal ArticleDOI
Actual causes of death in the United States, 2000.
TL;DR: These analyses show that smoking remains the leading cause of mortality in the United States, however, poor diet and physical inactivity may soon overtake tobacco as the lead cause of death.
Journal Article
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
UK Prospective Diabetes,Rury R. Holman,Susan E. Manley,R C Turner,Carole A. Cull,Irene M Stratton,Matthews,Michael Gnant +7 more
Journal ArticleDOI
The 12-month prevalence and trends in DSM-IV alcohol abuse and dependence: United States, 1991-1992 and 2001-2002.
Bridget F. Grant,Deborah A. Dawson,Frederick S. Stinson,S. Patricia Chou,Mary C. Dufour,Roger P. Pickering +5 more
TL;DR: In this paper, the authors present nationally representative data on the prevalence of 12-month DSM-IV alcohol abuse and dependence in 2001-2002 and examine trends in alcohol abuse between 1991-1992 and 2001- 2002.